SynthesisSurgical endoscopy2025
Risk assessment of lymph node metastasis and comparison of treatment modalities for low-risk T1b colorectal cancer: a meta-analysis.
Synthesis in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe uncertainty surrounding the risk of recurrence and metastasis in T1 colorectal cancer (CRC) with solely deep submucosal invasion (DSI, defined as T1b, submucosal invasion exceeding 1000 μm) as a high-risk factor has led to controversial treatment strategies. This meta-analysis aims to assess the risk of lymph node metastasis in T1 CRC patients presenting with a solitary risk factor of DSI. Furthermore, it compares the effectiveness and safety of endoscopic resection, surgery after endoscopic resection, and surgical resection in this context, offering valuable insights for clinical decision-making.
methodsPubMed, Embase, and the Cochrane Library electronic databases were searched to identify available studies published up to November 30, 2024. Random- or fixed-effects models were applied in the meta-analyses. Heterogeneity and consistency were evaluated.
resultsThe analysis encompassed 3331 cases of low-risk T1b CRC, pooled from 22 studies. The lymph node metastasis (LNM) rate of low-risk T1b CRC is 2.5% (95% CI 1.3-3.8%). Patients of this kind treated with endoscopic resection, surgery after endoscopic resection, or surgical resection alone do not differ statistically significantly in terms of recurrence rates (P = 0.28) or disease-specific survival (DSS) rate (P = 0.66). In addition, R0 resection could be achieved with endoscopic resection in the majority of patients, without serious adverse events reported in documented cases.
conclusionsFor patients with early-stage colorectal cancer presenting as DSI and devoid of other risk factors, treatment should be individualized. In such cases, given the low LNM rate, appropriately expanding the indications for endoscopic treatment and implementing rigorous follow-up post-endoscopic resection may represent a feasible strategy for selected patients, especially when balancing risks of unnecessary surgery. Otherwise, surgical resection remains the preferred treatment.
Indexed as
Identifiers
40987891What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.